Key Metrics
About the Show
Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast. Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.
Partnership & Audience Signals
Ads or sponsor reads already detected
Regularly hosts outside guests
100 episodes — long track record
Production & Distribution
Recent Episodes
Patrick Kelly & John Murphy: Generic Shortages and Supply Chain Risk
In this best-of edition of the Vital Health Podcast, we revisit two conversations Duane Schulthess has with experts on the future of generic medicines, drug shortages, and supply chain risk in the…
Christopher Locher: Why Vaccine Innovation Matters More Than Ever
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Christopher Locher, Chief Executive Officer at Versatope Therapeutics, about the current landscape for vaccine…
Melanie Whittington: Why Are Drugs So Expensive?
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Melanie Whittington, Managing Director and Head of the Leerink Center for Pharmacoeconomics and Senior Fellow at the…
VT's Grumpies and Lady Discuss the U.S. Biotech Policy Landscape
Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/ In this episode of the Vital Health Podcast, host Duane…
Tim Scott: MFN Pricing, Venture Risk, and the Future of California Biotech
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Tim Scott, President & CEO of Biocom California, a biopharma executive with more than two decades of experience,…
Mark Rohrbaugh & Gwen O’Loughlin: Drug Patents, March-In Rights, and NIH Technology Transfer
In this episode of the Vital Health Podcast, host Duane Schulthess examines how NIH-funded research fits into the U.S. innovation and IP ecosystem, and why today’s political rhetoric about…
Oriana Ciani & Denis Lacombe: Overall Survival and Surrogate Endpoints in Early Oncology Approvals
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on evidence standards for early oncology access at ISPOR Europe 2025 in Glasgow, Scotland: Oriana Ciani:…
Anja Schiel & Nicholas Hedberg: Accelerated Approvals, Evidence Gaps, and Reimbursement Risk
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts on reimbursement-facing evidence questions for accelerated oncology approvals at ISPOR Europe 2025 in…
Kathleen Grieve, Martina Garau, & Bettina Ryll: Accelerating Patient Access To Cancer Medicines In Europe
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three experts on accelerated patient access to cancer medicines at ISPOR Europe 2025 in Glasgow, Scotland: Martina…
2025 US Policy Highlights - Inflation Reduction Act (IRA) Part 2
In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug…
2025 US Policy Highlights - Most Favored Nation (MFN)
In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on Most Favored Nation (MFN) drug pricing and its knock-on effects for…
2025 U.S. Policy Highlights - Inflation Reduction Act (IRA) Part 1
In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug…
Steffen Thirstrup & Richard Bergstrom: Evidence, Access, and Competitiveness in Europe
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two experts in European regulation and evidence of new medicines: Steffen Thirstrup: Chief Medical Officer at European…
Malina Müller: Rethinking Accelerated Approvals in Europe
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Dr. Malina Müller, Head of Health Economics at WifOR Institute, to explore the heated debate around accelerated and…
VT's Grumpies Talk MFN
In this episode of the Vital Health Podcast, host Duane Schulthess sits down with two Vital Transformation colleagues to explore key trends in drug pricing and macroeconomic policy: Joe Hammang: US…
Bettina Ryll, Kjetil Taskén & Anni Lepland: PRIME-ROSE & EU Joint Action
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with three leaders advancing precision cancer medicine implementation in Europe: Bettina Ryll: Stockholm School of…
John Murphy: Generics, Biosimilars, and U.S. Policy
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medicines (AAM), to discuss how U.S. purchasing…
Patrick Kelly: Inside the Generic Supply Chain Squeeze
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Patrick Kelly, Chief Advocacy Officer at the Healthcare Distribution Alliance, to discuss why generic markets face…
Lieven Annemans & Andreas Charalambous: Moving the Needle in EU Cancer Care
In this Vital Health Podcast, host Duane Schulthess speaks with two leading European voices on oncology and health economics: Andreas Charalambous: Chair of Nursing at Cyprus University and…
Kirsten Axelsen: Part D Shift, IRA Penalties, and Access Risks
Kirsten Axelsen is an economist specializing in Medicare reimbursement, payer negotiations, and innovative reimbursement contracts. She’s a fellow of the Aspen Institute and a visiting scholar with…
Market Reports
Benchmark this show against its category and language peers.
Similar Podcasts
Comparable shows in the same category and language — useful for prospecting and competitive sets.
Profile compiled from public podcast metadata · Last refreshed June 15, 2026